Efficacy and Safety Evaluation of Nesiritide for Treating the Patients with Acute Decompensated Heart Failure
王国干,周玉杰,王海昌,陈君柱,魏盟,杨宏,高鑫,关键,李一石
DOI: https://doi.org/10.3969/j.issn.1000-3614.2009.05.011
2009-01-01
Abstract:Objective:To evaluate the efficacy and safety of intravenous(Ⅳ) infusion of nesiritide for treating acute decompensated heart failure by monitoring the hemodynamic parameters with Swan-Ganz Catheter. Methods:An open-label,one-arm clinical study was carried out by five cardiovascular research centers in China and 40 patients diagnosed for acute decompensated heart failure were enrolled.The hemodynamic parameters were monitored by Swan-Ganz Catheter.Pulmonary capillary wedge pressure(PCWP),pulmonary arterial pressure(PAP) and cardiac index(CI) were measured in all patients at different time points as immediately before drug administration,and 15 min,1 h,3 h and 24 h after drug administration.All patients received nesiritide at anⅣbolus of 2 ug/kg(approximately 60 seconds),followed byⅣinfusion at the flow rate of 0.01 ug/kg/min for 24 hours.Clinical index and adverse events were recorded. Results:PCWP(33.0±9.1,26.8±11.1,25.9±11.7,25.1±8.5 and 24.8±10.6 mmHg) and PAP(55.5±18.9, 49.2±21.6,47.8±22.1,46.9±20.0 and 45.2±21.8 mmHg) were significantly descended at different time points(base line,15 min,1 h,3 h,24 h after the administration).CI(1.97±0.62,2.32±0.75,2.26±0.67,2.23±0.61 and 2.2±0.53 L/min/m~2) were significantly increased.After using nesiritide,the blood pressure,heart rate and respiratory rate at each time point were decreased,clinical symptom was improved.No patient was withdrawal and no death during the experimental course. Conclusion:Nesiritide could significantly improve the hemodynamic parameters and clinical symptoms in patients with acute heart failure.